In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp

M A Pfaller; S A Messer; R J Hollis; R N Jones; D J Diekema

doi:10.1128/AAC.46.6.1723-1727.2002

Back

In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp

Journal article

Open access

Peer reviewed

In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp

M A Pfaller, S A Messer, R J Hollis, R N Jones and D J Diekema

Antimicrobial agents and chemotherapy, Vol.46(6), pp.1723-1727

06/2002

DOI: 10.1128/AAC.46.6.1723-1727.2002

PMCID: PMC127275

PMID: 12019081

Files and links (1)

url

https://doi.org/10.1128/AAC.46.6.1723-1727.2002View

Published (Version of record) Open Access

Abstract

The in vitro activities of ravuconazole and voriconazole were compared with those of amphotericin B, flucytosine (5FC), itraconazole, and fluconazole against 6,970 isolates of Candida spp. obtained from over 200 medical centers worldwide. Both ravuconazole and voriconazole were very active against all Candida spp. (MIC at which 90% of the isolates tested are inhibited [MIC(90)], 0.25 microg/ml; 98% of MICs were < or 1 microg/ml); however, a decrease in the activities of both of these agents was noted among isolates that were susceptible-dose dependent (fluconazole MIC, 16 to 32 microg/ml) and resistant (MIC, > or = 64 microg/ml) to fluconazole. Candida albicans was the most susceptible species (MIC(90) of both ravuconazole and voriconazole, 0.03 microg/ml), and C. glabrata was the least susceptible species (MIC(90), 1 to 2 microg/ml). Ravuconazole and voriconazole were each more active in vitro than amphotericin B, 5FC, itraconazole, and fluconazole against all Candida spp. and were the only agents with good in vitro activity against C. krusei. These results provide further evidence for the spectrum and potency of ravuconazole and voriconazole against a large and geographically diverse collection of Candida spp.

Antifungal Agents - pharmacology

Microbial Sensitivity Tests

Triazoles - pharmacology

Drug Resistance, Microbial

Humans

Voriconazole

Thiazoles - pharmacology

Candida - drug effects

Pyrimidines - pharmacology

Candidiasis - microbiology

Details

Title: Subtitle: In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp
Creators: M A Pfaller - Department of Pathology, University of Iowa College of Medicine, and College of Public Health, Iowa City, Iowa 52242, USA. michael-pfaller@uiowa.edu
S A Messer
R J Hollis
R N Jones
D J Diekema
Resource Type: Journal article
Publication Details: Antimicrobial agents and chemotherapy, Vol.46(6), pp.1723-1727
Publisher: United States
DOI: 10.1128/AAC.46.6.1723-1727.2002
PMID: 12019081
PMCID: PMC127275
ISSN: 0066-4804
eISSN: 1098-6596
Language: English
Date published: 06/2002
Academic Unit: Infectious Diseases; Epidemiology; Pathology; Internal Medicine
Record Identifier: 9983986366102771

Metrics

25 Record Views

193 Times Cited - Web of Science

See more details